Neil Gupta, Susan Swindells, Kimberly K Scarsi, Renae Furl, David L Thomas, Ethel D Weld, Joelle Dountio Ofimboudem, Hailemichael Desalegn, Saeed Hamid, Alethse de la Torre Rosas, Angelica E Miranda, Andrew Owen, Steve Rannard, Lindsey Hiebert, Katherine Sun, John W Ward
Long-acting technologies (LATs) for hepatitis C virus (HCV) are under development as a strategy to improve linkage to care, treatment adherence and outcomes. We conducted a survey of HCV treatment prescribers and HCV policymakers in low- and middle-income countries (LMICs) regarding acceptability and feasibility of HCV LATs. We included one-time intramuscular injection, subdermal implant and transdermal patch as potential LAT options. We surveyed participants regarding optimal health system and patient characteristics, concerns, potential barriers, overall feasibility and preferences for HCV LAT as compared to daily oral medication...
March 28, 2024: Journal of Viral Hepatitis